The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Flagged first, then by citations
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 301–400 of 1,002
Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 79
Cancer of Unknown Primary in the Molecular Era
Kato, S., Alsafar, A., Walavalkar, V., Hainsworth, J. D., & Kurzrock, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.11.002 · Cited by 77
The evolving landscape of tissue‐agnostic therapies in precision oncology
Subbiah, V., Gouda, M. A., Ryll, B., Burris, H. A., & Kurzrock, R. (2024) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21844 · Cited by 88
Self-citationUsing biology to guide the treatment of sarcomas and aggressive connective-tissue tumours
Dufresne, A., Brahmi, M., Karanian, M., & Blay, J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0012-4 · Cited by 77
Self-citationTwenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy
Jørgensen, J. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0054 · Cited by 81
Nunno, V. D., Gatto, L., Tosoni, A., Bartolini, S., & Franceschi, E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1067252 · Cited by 79
Bioinformatics for precision oncology
Singer, J., Irmisch, A., Ruscheweyh, H., Singer, F., Toussaint, N. C., Levesque, M. P., Stekhoven, D. J., & Beerenwinkel, N. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx143 · Cited by 81
Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
Knauf, J. A., Luckett, K. A., Chen, K.-Y., Voza, F. A., Socci, N. D., Ghossein, R. A., & Fagin, J. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120966 · Cited by 77
BRAF Mutated Colorectal Cancer: New Treatment Approaches
Molina‐Cerrillo, J., Román, M. S., Pozas, J., Alonso‐Gordoa, T., Pozas, M., Conde, E., Cancio-Suárez, M. R., Grande, E., García‐Bermejo, L., & Carrato, A. (2020) · Cancers · doi:10.3390/cancers12061571 · Cited by 78
Ross, J. S., Sokol, E. S., Moch, H., Mileshkin, L., Baciarello, G., Losa, F., Beringer, A., Thomas, M., Elvin, J. A., Ngo, N., et al. (2020) · The Oncologist · doi:10.1002/onco.13597 · Cited by 77
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Krenzien, F., Nevermann, N., Krombholz, A., Benzing, C., Haber, P., Fehrenbach, U., Lurje, G., Pelzer, U., Pratschke, J., Schmelzle, M., et al. (2022) · Cancers · doi:10.3390/cancers14020362 · Cited by 78
Hazar-Rethinam, M. H., Kleyman, M., Han, G. C., Liu, D., Ahronian, L. G., Shahzade, H. A., Chen, L., Parikh, A. R., Allen, J. N., Clark, J. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1227 · Cited by 77
Self-citation“Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”?
Kolling, S., Ventre, F., Geuna, E., Milan, M., Pisacane, A. M., Boccaccio, C., Sapino, A., & Montemurro, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01546 · Cited by 74
Al-Wahaibi, L. H., Gouda, A. M., Abou‐Ghadir, O. F., Salem, O. I. A., Ali, A. T., Farghaly, H. S., Abdelrahman, M. H., Trembleau, L., Abdu-Allah, H. H. M., & Youssif, B. G. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104260 · Cited by 75
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer
Melosky, B. L., Wheatley‐Price, P., Juergens, R. A., Sacher, A. G., Leighl, N. B., Tsao, M., Cheema, P. K., Snow, S. L., Liu, G., Card, P. B., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.002 · Cited by 75
Brägelmann, J., Lorenz, C., Borchmann, S., Nishii, K., Wegner, J., Meder, L., Ostendorp, J., Ast, D., Heimsoeth, A., Nakasuka, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25728-8 · Cited by 79
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
Yan, N., Guo, S., Zhang, H., Zhang, Z., Shen, S., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.863043 · Cited by 80
Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease
Aubart, F. C., Emile, J., Maksud, P., Damien Galanaud, E., Cluzel, P., Benameur, N., Aumaître, O., Amoura, Z., & Haroche, J. (2016) · British Journal of Haematology · doi:10.1111/bjh.14284 · Cited by 75
Dashti, N. K., Bahrami, A., Lee, S. J., Jenkins, S. M., Rodríguez, F. J., Folpe, A. L., & Boland, J. M. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000913 · Cited by 75
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Taı̈eb, J., Lapeyre-Prost, A., Laurent‐Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 76
Tumor slice culture as a biologic surrogate of human cancer
Kenerson, H. L., Sullivan, K. M., Seo, Y. D., Stadeli, K. M., Ussakli, C., Yan, X., Lausted, C., Pillarisetty, V. G., Park, J. O., Riehle, K. J., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2019.12.88 · Cited by 74
Multiple myeloma with central nervous system relapse
Egan, P. A., Elder, P. T., Deighan, W. I., O’Connor, S. J. M., & Alexander, H. D. (2020) · Haematologica · doi:10.3324/haematol.2020.248518 · Cited by 76
Lorusso, L., Cappagli, V., Valerio, L., Giani, C., Viola, D., Puleo, L., Gambale, C., Minaldi, E., Campopiano, M. C., Matrone, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063117 · Cited by 79
Limited evolution of the actionable metastatic cancer genome under therapeutic pressure
van de Haar, J., Hoes, L. R., Roepman, P., Lolkema, M. P., Verheul, H. M. W., Gelderblom, H. A. J., Langen, A. J. D., Smit, E. F., Cuppen, E. P. J. G., Wessels, L. F. A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01448-w · Cited by 74
MEK inhibitors under development for treatment of non-small-cell lung cancer
Kim, C. G., & Giaccone, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1415324 · Cited by 73
Erdheim-Chester Disease: a Concise Review
Papo, M., Emile, J., Maciel, T. T., Bay, P., Baber, A., Hermine, O., Amoura, Z., & Haroche, J. (2019) · Current Rheumatology Reports · doi:10.1007/s11926-019-0865-2 · Cited by 73
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
Goyal, G., Shah, M. V., Call, T. G., Litzow, M. R., Hogan, W. J., & Go, R. S. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0041 · Cited by 73
Hutter, C., & Minkov, M. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s91058 · Cited by 72
Dalton, H. J., Fleming, N. D., Sun, C. C., Bhosale, P., Schmeler, K. M., & Gershenson, D. M. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.01.027 · Cited by 72
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Garbe, C., & Eigentler, T. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_6 · Cited by 72
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Reilley, M. J., Bailey, A. M., Subbiah, V., Jankú, F., Naing, A., Falchook, G. S., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Fu, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0238-1 · Cited by 71
Self-citationMolecular Testing for Gastrointestinal Cancer
Lee, H. S., Kim, W. H., Kwak, Y., Koh, J., Bae, J. M., Kim, K., Chang, M. S., Han, H. S., Kim, J. M., Kim, H. W., et al. (2017) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2017.01.24 · Cited by 71
Westphalen, C. B., Martins-Branco, D. A., Beal, J. R., Cardone, C., Coleman, N., Schram, A. M., Halabi, S., Michiels, S., Yap, C., André, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.07.730 · Cited by 74
Self-citationTargeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Wang, W., Kang, H. H., Zhao, Y., Min, I. M., Wyrwas, B., Moore, M. D., Teng, L., Zarnegar, R., Jiang, X., & Fahey, T. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1999 · Cited by 71
Innovation in oncology clinical trial design
Verweij, J., Hendriks, H. R., Zwierzina, H., Hanauske, Wacheck, V., Collignon, O., Bruzzi, P., Gross, J., Riehl, T., Bretz, F., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.001 · Cited by 73
Intrahepatic cholangiocarcinoma: current management and emerging therapies
Rahnemai‐Azar, A. A., Weisbrod, A. B., Dillhoff, M. E., Schmidt, C. R., & Pawlik, T. M. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1309290 · Cited by 69
Options for Treating Different Soft Tissue Sarcoma Subtypes
Ray-Coquard, I. L., Serre, D., Reichardt, P., Martín‐Broto, J., & Bauer, S. (2018) · Future Oncology · doi:10.2217/fon-2018-0076 · Cited by 69
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF V600E-Mutant Brain Tumor
Wang, J., Yao, Z., Jonsson, P., Allen, A. N., Qin, A. C. R., Uddin, S., Dunkel, I. J., Petriccione, M., Manova, K., Haque, S. S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1263 · Cited by 69
Targeting BRAF and RAS in Colorectal Cancer
Bellio, H., Fumet, J.-D., & Ghiringhelli, F. (2021) · Cancers · doi:10.3390/cancers13092201 · Cited by 71
The Evolving Treatment Landscape in BRAF-V600E –Mutated Metastatic Colorectal Cancer
Tabernero, J. M., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 71
Self-citationBiphasic regulation of osteoblast development via the ERK MAPK–mTOR pathway
Kim, J., Yang, Y.-S., Hong, J., Chaugule, S. R., Chun, H., van der Meulen, M. C. H., Xu, R., Greenblatt, M. B., & Shim, J. (2022) · eLife · doi:10.7554/elife.78069 · Cited by 72
Tumino, D., Frasca, F., & Newbold, K. L. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00312 · Cited by 71
Subbiah, V., Gervais, R., Riely, G. J., Hollebecque, A., Blay, J., Felip, E., Schüler, M., Gonçalvès, A., Italiano, A., Keedy, V. L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00266 · Cited by 71
Self-citationWiesweg, M., Eberhardt, W., Reis, H., Ting, S. C., Savvidou, N., Skiba, C., Herold, T., Christoph, D. C., Meiler, J., Worm, K., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.137 · Cited by 69
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary
Conway, A., Pearce, S. P., Clipson, A., Hill, S. M., Chemi, F., Slane-Tan, D., Ferdous, S., Hossain, A., Kamieniecka, K., White, D. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47195-7 · Cited by 74
Keyl, J., Keyl, P., Montavon, G., Hosch, R., Brehmer, A., Mochmann, L. H., Jurmeister, P. S., Dernbach, G., Kim, M., Koitka, S., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00891-1 · Cited by 79
Liquid Biopsy: From Basic Research to Clinical Practice
Macías, M., Alegre, E., Díaz‐Lagares, Á., Patiño‐García, A., Perez‐Gracia, J. L., Sanmamed, M. F., López‐López, R., Varo, N., & González, Á. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.10.003 · Cited by 71
Do immune checkpoint inhibitors need new studies methodology?
Ferrara, R., Pilotto, S., Caccese, M., Grizzi, G., Sperduti, I., Giannarelli, D., Milella, M., Besse, B., Tortora, G., & Bria, E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.131 · Cited by 69
Zhou, G. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0180 · Cited by 70
Precision Medicine in Biliary Tract Cancer
Scott, A. J., Sharman, R., & Shroff, R. T. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02576 · Cited by 68
The molecular pathology of ovarian serous borderline tumors
Malpica, A. L., & Wong, K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw089 · Cited by 67
Dabrafenib and trametinib in BRAFV600E mutated glioma
Brown, N. F., Carter, T. J., Kitchen, N. D., & Mulholland, P. J. (2017) · CNS Oncology · doi:10.2217/cns-2017-0006 · Cited by 67
Lin, Q. D., Zhang, H., Ding, H., Qian, J., Lizaso, A., Lin, J., Han‐Zhang, H., Xiang, J., Li, Y., & Zhu, H. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2036-7 · Cited by 67
Marron, J. M., DuBois, S. G., Bender, J. G., Kim, A., Crompton, B. D., Meyer, S. C., Janeway, K. A., & Mack, J. W. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26137 · Cited by 70
A systematic review of targeted agents for non-small cell lung cancer
Vestergaard, H. H., Christensen, M. R., & Lassen, U. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1404634 · Cited by 66
Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 70
Batis, N., Brooks, J. M., Payne, K. F. B., Sharma, N., Nankivell, P., & Mehanna, H. M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113854 · Cited by 68
Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations
Tran, G., Huynh, T. N., & Paller, A. S. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.022 · Cited by 65
Molecular Markers Guiding Thyroid Cancer Management
Nylén, C., Mechera, R., Maréchal-Ross, I., Tsang, V., Chou, A. S. Y., Gill, A. J., Clifton-Bligh, R. J., Robinson, B. G., Sywak, M. S., Sidhu, S. B., et al. (2020) · Cancers · doi:10.3390/cancers12082164 · Cited by 67
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 68
Self-citationRos, J., Matito, J., Villacampa, G. J., Comas, R., García, A., Martini, G., Baraibar, I., Gonzalez, N. S., Salvà, F., Martín, Á., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.016 · Cited by 67
Self-citationBRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen, R., Cervera, P., Svrcek, M., Pellat, A., Dreyer, C., de Gramont, A., & André, T. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0453-5 · Cited by 64
Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules
de Koster, E. J., de Geus‐Oei, L., Dekkers, O. M., Grunsven, I. V. E., Hamming, J. F., Corssmit, E. P. M., Morreau, H. M., Schepers, A., Smit, J. W. A., Oyen, W. J. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00133 · Cited by 66
Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., García, A., Alcaráz, A., Vega, S., Bueno, S., Tabernero, J. M., et al. (2023) · Cancers · doi:10.3390/cancers15164020 · Cited by 64
Self-citationDing, X., Zhang, Z., Jiang, T., Li, X., Zhao, C., Su, B., & Zhou, C. (2017) · Cancer Medicine · doi:10.1002/cam4.1014 · Cited by 63
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
BRAF V600E mutation detected in a case of Rosai-Dorfman disease
Fatobene, G., Haroche, J., Hélias‐Rodzewicz, Z., Charlotte, F., Taly, V., Ferreira, A. M., Abdo, A., Rocha, V., & Emile, J. (2018) · Haematologica · doi:10.3324/haematol.2018.190934 · Cited by 63
Agents to treat BRAF-mutant lung cancer
Alvarez, J. G. B., & Otterson, G. A. (2019) · Drugs in Context · doi:10.7573/dic.212566 · Cited by 65
Gröschel, S., Bommer, M., Hutter, B., Budczies, J., Bonekamp, D., Heining, C., Horak, P., Fröhlich, M., Uhrig, S., Hübschmann, D., et al. (2016) · Molecular Case Studies · doi:10.1101/mcs.a001180 · Cited by 61
Seligson, N. D., Knepper, T. C., Ragg, S., & Walko, C. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1946 · Cited by 62
Lu, C. C., Li, X. N., Broglio, K. R., Bycott, P. W., Jiang, Q., Li, X., McGlothlin, A. E., Tian, H., & Ye, J. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00315-7 · Cited by 64
Gomaa, H. A. M., Shaker, M. E., Alzarea, S. I., Hendawy, O. M., Mohamed, F. A., Gouda, A. M., Ali, A. T., Morcoss, M. M., Abdelrahman, M. H., Trembleau, L., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105616 · Cited by 62
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications
Gouda, M. A., Nelson, B. E., Buschhorn, L., Wahida, A., & Subbiah, V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0090 · Cited by 70
Self-citationNordmann, T. M., Juengling, F. D., Recher, M., Berger, C. T., Kalbermatten, D. F., WICKI, A. N., Paasinen-Sohns, A., Cathomas, G., Tzankov, A., & Daikeler, T. D. (2016) · Blood · doi:10.1182/blood-2016-09-740217 · Cited by 62
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance
Gao, X., Chen, G., Gao, C., Zhang, D. H., Kuan, S., Stabile, L. P., Liu, G., & Hu, J. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12055 · Cited by 62
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 65
Bayesian adaptive basket trial design using model averaging
Psioda, M. A., Xu, J., Jiang, Q., Ke, C., Yang, Z., & Ibrahim, J. G. (2019) · Biostatistics · doi:10.1093/biostatistics/kxz014 · Cited by 61
Lavingia, V. K., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.13 · Cited by 61
The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer
Bahrami, A., Hesari, A., Khazaei, M., Hassanian, S. M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25952 · Cited by 60
Uijen, M. J. M., Lassche, G., Grunsven, A. C. H. V. E., Tada, Y., Verhaegh, G. W. C. T., Schalken, J. A., Driessen, C. M. L., & van Herpen, C. M. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102069 · Cited by 62
Robb, R. N., Yang, L., Shen, C., Wolfe, A. R., Webb, A., Zhang, X., Vedaie, M., Saji, M., Jhiang, S. M., Ringel, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3625 · Cited by 60
Actionable Molecular Biomarkers in Primary Brain Tumors
Staedtke, V., Dzaye, O. D. A., & Holdhoff, M. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.06.003 · Cited by 59
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Zhang, Y.-C., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0536-6 · Cited by 60
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling
Gargano, S., Senarathne, W., Feldman, R. A., Florento, E., Stafford, P., Swensen, J. J., Vranić, S., & Gatalica, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2602 · Cited by 62
Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series
Bhatia, A., Hatzoglou, V., Ulaner, G. A., Rampal, R. K., Hyman, D. M., Abdel-Wahab, O. I., Durham, B. H., Doǧan, A., Özkaya, N., Yabe, M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa008 · Cited by 59
Self-citationAdvances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59
Nutritional Genomics and Direct-to-Consumer Genetic Testing: An Overview
Guasch‐Ferré, M., Dashti, H. S., & Merino, J. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy001 · Cited by 64
Noorani, I., Mischel, P. S., & Swanton, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00679-1 · Cited by 55
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Rustad, E. H., Coward, E., Skytøen, E. R., Misund, K., Holien, T., Standal, T., Børset, M., Beisvåg, V., Myklebost, O., Meza‐Zepeda, L. A., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.160564 · Cited by 58
Li, S. D., Ma, M., Li, H., Waluszko, A., Sidorenko, T., Schadt, E. E., Zhang, D. Y., Chen, R., & Ye, F. (2017) · Genome Medicine · doi:10.1186/s13073-017-0478-1 · Cited by 58
Ikeda, S., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1523849 · Cited by 59
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier, T., Fernández, E., Labidi‐Galy, S. I., Dietrich, P., Rodríguez-Bravo, V., Baciarello, G., Fizazi, K. S., & Patrikidou, A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102204 · Cited by 57
Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics
Abe, I., & Lam, A. K.-Y. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01019-9 · Cited by 57
Defining and Targeting BRAF Mutations in Solid Tumors
Halle, B. R., & Johnson, D. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00827-2 · Cited by 53
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Egeler, R. M., Katewa, S., Leenen, P. J. M., Beverley, P. C. L., Collin, M. P., Ginhoux, F., Arceci, R. J., & Rollins, B. J. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26104 · Cited by 56
Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features
Yue, Q., Yu, Y. W., Shi, Z., Wang, Y., Zhu, W. P., Du, Z., Yao, Z., Chen, L., & Mao, Y. Q. (2017) · Journal of neurosurgery · doi:10.3171/2017.4.jns163113 · Cited by 57
Bisschop, C., ter Elst, A., Bosman, L. J., Platteel, I., Jalving, M., van den Berg, A., Diepstra, A., van Hemel, B. M., Diercks, G. F. H., Hospers, G. A. P., et al. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000421 · Cited by 56
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
